Related Experiment Video

Updated: Jul 26, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.4K

CAR-T therapy for multiple myeloma in China. Does it make sense financially?

Panagiotis Petrou1

  • 1Senior Officer, Health Insurance Organization Department of Life and Health Sciences, School of Pharmacy, Pharmacoepidemiology-Pharmacovigilance, University of Nicosia, Nicosia, Cyprus.

Journal of Medical Economics
|June 12, 2023
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.4K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

673

Related Experiment Videos

Last Updated: Jul 26, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.4K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.4K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

673

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K

Articles linked to this work by shared authors, journal, and citation graph.

Cost-neutral adoption of anti-VEGF therapies in neovascular age-related macular degeneration.

Expert review of pharmacoeconomics & outcomes research·2026

National outpatient antibiotic prescriptions in Cyprus, 2020-2022.

Antimicrobial stewardship & healthcare epidemiology : ASHE·2025

Can Cyprus Afford Luspatercept? A Budget Impact Analysis of the Reimbursement of Luspatercept for the Management of Thalassaemia in Cyprus.

PharmacoEconomics - open·2024

Implementing a Managed Entry Agreement Framework in Cyprus.

Expert review of pharmacoeconomics & outcomes research·2023

Is it a chimera? A systematic review of the economic evaluations of CAR-T cell therapy - an update.

Expert review of pharmacoeconomics & outcomes research·2023

Assessing the pricing and benefits of oncology products: an update.

Expert review of pharmacoeconomics & outcomes research·2021

The ongoing challenge of Clostridioides difficile infection in Austria: economic evaluation of two recommended treatment pathways.

Journal of medical economics·2026

The economic impact of pediatric RSV-related lower respiratory tract infection in Germany: evidence from the PAPI study.

Journal of medical economics·2026

Cost-effectiveness of perioperative pembrolizumab plus enfortumab vedotin for cisplatin-ineligible or cisplatin-declining patients with muscle-invasive bladder cancer in the United States.

Journal of medical economics·2026

Impact on health outcomes of treating all eligible large B-cell lymphoma patients with axicabtagene ciloleucel in Portugal - A modeling approach.

Journal of medical economics·2026

Real-world all-cause healthcare resource utilization and costs among patients with interstitial cystitis/bladder pain syndrome in the United States.

Journal of medical economics·2026

Cost-effectiveness of pembrolizumab as neoadjuvant therapy and in combination with standard of care (SOC) as adjuvant therapy for stage III-IVA resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC) in Switzerland.

Journal of medical economics·2026

Global financing of strabismus surgery: a literature review supported by an international survey.

Strabismus·2026

Acceptance sampling-based investment indicators for financial security selection and portfolio optimization.

Journal of applied statistics·2026

The Determinants of Profitability in Iran's Pharmaceutical Industry: A Panel Data Analysis.

Medical journal of the Islamic Republic of Iran·2026

Beyond the Transaction: Commitment, Intimacy, and Investment in Online Camming Relationships.

Archives of sexual behavior·2026

The Association Between Insurance Type and Financial Toxicity in Older Adult Surgical Patients.

The Journal of surgical research·2026

Fintech-driven sport event sponsorship: how commercial banks' innovative marketing strategies shape destination branding and inclusive tourism.

Frontiers in sports and active living·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us